CLINICAL TRIALS PROFILE FOR CEFPODOXIME PROXETIL

All Clinical Trials for cefpodoxime proxetil

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	James Graham Brown Cancer Center	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	University of Louisville	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	Julio Ramirez	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT03491748 ↗	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants	Completed	Entasis Therapeutics	Phase 1	2018-03-16	This research project is being conducted to investigate the safety, tolerability, and pharmacokinetics (PK) of a single ascending dose (SAD) and multiple ascending doses (MAD) of oral ETX0282 when administered alone and in combination with cefpodoxime proxetil in healthy adult participants.

Clinical Trial Conditions for cefpodoxime proxetil

Condition Name

Condition Name for cefpodoxime proxetil
Intervention	Trials
Osteomyelitis	1
Healthy Volunteers	1

Condition MeSH

Condition MeSH for cefpodoxime proxetil
Intervention	Trials
Osteomyelitis	1

Clinical Trial Locations for cefpodoxime proxetil

Trials by Country

Trials by Country for cefpodoxime proxetil
Location	Trials
Australia	1
United States	1

Trials by US State

Trials by US State for cefpodoxime proxetil
Location	Trials
Kentucky	1

Clinical Trial Progress for cefpodoxime proxetil

Clinical Trial Phase

Clinical Trial Phase for cefpodoxime proxetil
Clinical Trial Phase	Trials
Phase 1	1
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for cefpodoxime proxetil
Clinical Trial Phase	Trials
Terminated	1
Completed	1

Clinical Trial Sponsors for cefpodoxime proxetil

Sponsor Name

Sponsor Name for cefpodoxime proxetil
Sponsor	Trials
Entasis Therapeutics	1
James Graham Brown Cancer Center	1
University of Louisville	1

Sponsor Type

Sponsor Type for cefpodoxime proxetil
Sponsor	Trials
Other	3
Industry	1

Cefpodoxime proxetil Market Analysis and Financial Projection

Last updated: April 25, 2026

Cefpodoxime Proxetil Clinical Trials Update and Market Projection

What is cefpodoxime proxetil and what is its current development posture?

Cefpodoxime proxetil is an oral, prodrug form of the cephalosporin antibiotic cefpodoxime used for bacterial infections. As a marketed, off-patent small-molecule antibiotic with broad global availability, the “clinical trials update” in practice is dominated by:

• Safety/efficacy studies tied to specific indications, pediatric subpopulations, and comparator designs
• Bioequivalence (BE) studies for generics and formulation changes
• Real-world evidence (RWE) publications, which do not carry the same commercial risk allocation as registrational Phase 3

Result: There is no credible basis to treat the global pipeline as led by new cefpodoxime proxetil proprietary development that would change peak market outcomes. The market outlook is instead driven by (1) guideline behavior, (2) antibiotic stewardship constraints, (3) payer procurement and generic penetration, and (4) region-specific incidence and resistance patterns.

What do current clinical trial updates look like?

A practical way to scope “current clinical trials updates” for an older antibiotic is to separate:

1. Registrational-intent trials (rare for an off-patent product)
2. Generic BE and formulation trials (frequent)
3. Observational studies and audits (common)

For cefpodoxime proxetil, the dominant volume in public trial registries is typically generic BE and infection-specific small studies. The commercial implication is that these trials generally:

• do not create new exclusivity
• do not expand label breadth materially
• do not meaningfully alter pricing power

Actionable takeaway for R&D and investment: Treat cefpodoxime proxetil’s “clinical trials update” as pipeline maintenance (BE, label-locational studies) rather than new therapeutic momentum. Any growth opportunity will come from channel mix and procurement, not from new clinical differentiation.

---

What is the current market structure for cefpodoxime proxetil?

Where does cefpodoxime proxetil sit in antibiotics category dynamics?

Cefpodoxime proxetil competes in:

• Oral cephalosporins
• Community-acquired bacterial infection segments (ear, throat, skin, urinary tract, respiratory where approved in-market)
• Empiric outpatient pathways where stewardship supports narrow-spectrum and local resistance patterns

Market reality: Oral cephalosporins face persistent pressure from:

• guideline-driven first-line selection shifts (penicillins, macrolides, doxycycline-like options where appropriate)
• increasing use of tests (culture, rapid antigen)
• payer drives toward lowest acquisition cost within a therapeutic equivalence envelope

Generic penetration is the dominant driver

Cefpodoxime proxetil is widely generic. The competitive pattern across major markets is:

• multiple low-cost manufacturers
• ongoing BE filings
• price compression as procurement cycles favor tenders and formularies

---

Market analysis: size, segmentation, and demand drivers

How do key demand drivers move the category?

Cefpodoxime proxetil demand is primarily a function of:

• Infection incidence in outpatient care (pediatrics and ENT are typical volume centers for oral cephalosporins)
• Formulary positioning (presence on payer lists, tier status, prior authorization rules)
• Resistance pattern shifts impacting antibiotic selection
• Stewardship constraints limiting empiric broad use in some settings

What limits upside versus higher-value antibiotics?

Unlike newer agents with differentiated MoA or resistance strategies, cefpodoxime proxetil is constrained by:

• generic-led pricing ceilings
• stewardship and guideline churn away from older cephalosporins in some geographies
• limited ability to re-accelerate growth without new label expansion

---

How should market projections be built for cefpodoxime proxetil?

Projection framework that aligns with how generic antibiotics perform

A credible projection for cefpodoxime proxetil must treat the product as a mature, generic antibiotic with revenue shaped by:

• unit demand (stable or slowly declining depending on infection mix and stewardship)
• average selling price (ASP) (structurally pressured by generic competition)
• geography mix (countries with tender-driven price erosion vs. markets with slower discounting)
• substitution effects (switching between oral beta-lactams and alternative outpatient regimens)

Base-case projection (conceptual)

Given the mature, generic posture, the base-case outcome typically follows:

• modest unit growth or stability
• declining or flat ASP
• flat-to-low single digit revenue growth over multi-year horizons, with periodic dips tied to procurement cycles

Upside and downside bands

• Upside band: improved formulary retention in key outpatient channels, stable resistance, and localized price floors.
• Downside band: additional stewardship restrictions, guideline displacement to alternatives, and aggressive tender pricing.

Business implication: For investors, the lever is not “clinical efficacy gains,” it is supply chain reliability, tender execution, and formulary defense.

---

What does the competitive landscape imply for revenue durability?

Competitor set for substitution

Cefpodoxime proxetil substitution risk comes from:

• other oral cephalosporins (different prescribing and spectrum positions)
• amoxicillin-clavulanate and other beta-lactams
• macrolides or alternatives depending on region and resistance

Procurement and tender cycles are the revenue control points

For generic antibiotics:

• revenues can hold even with declining global category growth if procurement share is defended
• revenues can fall sharply if a tender replaces one supplier or squeezes ASP further

---

Key Takeaways

• Cefpodoxime proxetil’s clinical activity is mostly consistent with mature-market needs (BE and small infection-focused studies), not label-breaking registrational development.
• Market outcomes are driven by generic competition, stewardship-linked prescribing, and formulary/tender execution, not by new clinical differentiation.
• Projections should model stable-to-slow unit demand with structurally pressured ASP, yielding flat-to-low single-digit revenue growth in base cases.

---

FAQs

1) Does cefpodoxime proxetil have ongoing registrational Phase 3 development that could expand global label?

No material label-expanding registrational development is the expected pattern for an off-patent, widely generic antibiotic. Clinical activity is more commonly BE/formulation and smaller infection-specific studies.

2) What most affects cefpodoxime proxetil revenue over the next 3 to 5 years?

ASP compression from generic competition and formulary/tender placement in major outpatient channels.

3) Is resistance a net positive or negative for cefpodoxime proxetil demand?

Resistance patterns can influence prescribing, but for a generic beta-lactam class the dominant demand swing is guideline placement and stewardship controls, which can be regionally variable.

4) Where is substitution risk highest?

Where payers steer to lowest-cost therapeutically acceptable oral antibiotics and where guidelines favor alternatives for common outpatient infections.

5) What is the most practical growth lever for manufacturers of cefpodoxime proxetil?

Execution in procurement cycles and maintaining supply reliability and formulary position rather than relying on new clinical differentiation.

---

References

[1] European Medicines Agency (EMA). Cefpodoxime proxetil: product information and related assessments.
[2] U.S. Food and Drug Administration (FDA). Cefpodoxime proxetil: approved labeling and related review documents.
[3] ClinicalTrials.gov. Search results for “cefpodoxime proxetil” and “cefpodoxime proxetil bioequivalence” (accessed 2026-04-25).
[4] World Health Organization (WHO). Antimicrobial resistance and stewardship guidance relevant to outpatient antibiotic use.